Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Non-Current Assets (2016 - 2025)

Alterity Therapeutics has reported Non-Current Assets over the past 5 years, most recently at $34146.6 for Q2 2019.

  • For Q2 2019, Non-Current Assets fell 36.85% year-over-year to $34146.6; the TTM value through Jun 2019 reached $34146.6, down 36.85%, while the annual FY2019 figure was $34146.6, 36.85% down from the prior year.
  • Non-Current Assets for Q2 2019 was $34146.6 at Alterity Therapeutics, up from $43.04 in the prior quarter.
  • Over five years, Non-Current Assets peaked at $59903.9 in Q4 2016 and troughed at $23.14 in Q2 2017.
  • A 5-year average of $24923.2 and a median of $19384.4 in 2017 define the central range for Non-Current Assets.
  • On a YoY basis, Non-Current Assets climbed as much as 233588.21% in 2018 and fell as far as 99.78% in 2018.
  • Year by year, Non-Current Assets stood at $56618.0 in 2015, then increased by 5.8% to $59903.9 in 2016, then tumbled by 67.64% to $19384.4 in 2017, then crashed by 99.78% to $43.04 in 2018, then soared by 79229.96% to $34146.6 in 2019.
  • Business Quant data shows Non-Current Assets for ATHE at $34146.6 in Q2 2019, $43.04 in Q4 2018, and $54069.1 in Q2 2018.